Clinical Trial

Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease

Study acronym: RIGID
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Previous studies have shown that there is a large inter-individual variability in the degree of bone loss during glucocorticoid treatment, and while some patients experience extensive bone loss other patients\' bone mass remains stable. The aim of the study is to find a biomarker that can be used to identify individuals at risk of glucocorticoid-induced bone loss. The study will include 36 healthy volunteers, that will be randomized to receive either glucocorticoid treatment or placebo. During the study blood samples, bone marrow samples, bone tissue samples, and adipose tissue samples are taken and an oral glucose tolerance test is performed.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-05-14; most recent amendment 2026-03-31.
Status change: Recruiting → Active, Not Recruiting 2026-03-31
Status change: Not Yet Recruiting → Recruiting 2024-11-27
Trial Details
NCT Number NCT06421597
Lead Sponsor Odense University Hospital
Collaborators: Esbjerg Hospital - University Hospital of Southern Denmark, University of Ulm, University of Birmingham
Conditions Osteoporosis Secondary
Enrollment 36 participants
Start Date 2024-11-04
Primary Completion 2026-03-30 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2026-04-06